We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+0.81%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$328M
AUM Growth
-$55.1M
Cap. Flow
-$44.7M
Cap. Flow %
-13.62%
Top 10 Hldgs %
42.21%
Holding
136
New
34
Increased
27
Reduced
16
Closed
41

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$14.8M
2
SLNO
Soleno Therapeutics
SLNO
+$14.3M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.24M
4
TGTX icon
TG Therapeutics
TGTX
+$6.09M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$4.61M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.5M
2
ARGX icon
argenx
ARGX
+$3.66M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.54M
4
LLY icon
Eli Lilly
LLY
+$3.49M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$2.65M

Sector Composition

Rank Sector Weight
1 Healthcare 49.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATYR
76
CALL
aTyr Pharma
ATYR
$47.6M
$653K 0.2%
128,700
+74,000
+135% +$291K
PRTA icon
77
CALL
Prothena Corp
PRTA
$425M
$607K 0.18%
+100,000
New +$751K
TERN
78
CALL
DELISTED
Terns Pharmaceuticals
TERN
$600K 0.18%
+160,900
New +$503K
APGE icon
79
Apogee Therapeutics
APGE
$10.1B
$459K 0.14%
10,572
-29,428
-74% -$1.12M
PHAT icon
80
Phathom Pharmaceuticals
PHAT
$708M
$386K 0.12%
+40,294
New +$223K
ATYR
81
PUT
aTyr Pharma
ATYR
$47.6M
$386K 0.12%
76,200
+64,400
+546% +$253K
NUVL
82
DELISTED
Nuvalent
NUVL
$382K 0.12%
+5,000
New +$366K
ALEC icon
83
Alector
ALEC
$168M
$372K 0.11%
266,023
-190,523
-42% -$239K
PRQR icon
84
ProQR Therapeutics
PRQR
$243M
$322K 0.1%
157,694
-50,000
-24% -$81.3K
REPL icon
85
Replimune Group
REPL
$941M
$302K 0.09%
32,483
-42,047
-56% -$367K
ELDN icon
86
Eledon Pharmaceuticals
ELDN
$261M
$175K 0.05%
64,613
– –
RLAY icon
87
Relay Therapeutics
RLAY
$4.1B
$151K 0.05%
43,616
-382,730
-90% -$1.14M
ELEV
88
DELISTED
Elevation Oncology
ELEV
$133K 0.04%
+362,935
New +$121K
PRTC
89
DELISTED
PureTech Health
PRTC
$126K 0.04%
+7,324
New +$129K
MREO
90
PUT
Mereo BioPharma
MREO
$54.7M
$107K 0.03%
39,400
– –
NKTR icon
91
CALL
Nektar Therapeutics
NKTR
$2.39B
$85.9K 0.03%
47,474
+2,261
+5% +$25.4K
COGT icon
92
CALL
Cogent Biosciences
COGT
$6.65B
$49.5K 0.02%
+6,900
New +$38.3K
SMMT icon
93
Summit Therapeutics
SMMT
$10.4B
$19.8K 0.01%
+932
New +$21.3K
ZLAB icon
94
Zai Lab
ZLAB
$2.06B
$13.2K ﹤0.01%
+3,785
New +$124K
VTGN icon
95
CALL
VistaGen Therapeutics
VTGN
$9.89M
$400 ﹤0.01%
200
– –
ALNY icon
96
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-13,115
Closed -$3.54M
ALNY icon
97
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-20,000
Closed -$5.4M
AMGN icon
98
CALL
Amgen
AMGN
$208B
– –
-103,300
Closed -$32.2M
ANAB icon
99
CALL
AnaptysBio
ANAB
$1.58B
– –
-96,800
Closed -$1.8M
ANAB icon
100
PUT
AnaptysBio
ANAB
$1.58B
– –
-117,300
Closed -$2.18M
2 3
4
5 6

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Diadema Partners held 136 positions worth $328M, down 14% from $383M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Diadema Partners withdrew a net $44.7M in Q2 2025, closing 41 positions and reducing 16 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $3.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 33% a quarter earlier.

Against the trend, Diadema Partners opened a new position in Amgen worth $14.5M.

  • Diadema Partners's largest Q2 2025 buy was Amgen: 52,100 shares worth $14.5M.
  • Diadema Partners added most to Soleno Therapeutics in Q2 2025, an estimated $14.3M increase.
  • Diadema Partners's biggest Q2 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $13.5M.
  • Diadema Partners fully exited Alnylam Pharmaceuticals in Q2 2025, selling an estimated $3.54M.
  • Diadema Partners's ten largest holdings make up 42% of its $328M portfolio in Q2 2025.
  • Diadema Partners opened 34 new positions and closed 41 in Q2 2025.
  • Diadema Partners's portfolio value fell 14% quarter-over-quarter to $328M.

Based on Diadema Partners's 13F filing for Q2 2025, filed 14 Aug 2025.